- Home
- IHD vs SGMO Comparison
IHD vs SGMO Comparison
Compare IHD & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IHD
- SGMO
- Stock Information
- Founded
- IHD 2011
- SGMO 1995
- Country
- IHD United States
- SGMO United States
- Employees
- IHD N/A
- SGMO N/A
- Industry
- IHD Investment Managers
- SGMO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IHD Finance
- SGMO Health Care
- Exchange
- IHD Nasdaq
- SGMO Nasdaq
- Market Cap
- IHD 108.0M
- SGMO 122.8M
- IPO Year
- IHD N/A
- SGMO 2000
- Fundamental
- Price
- IHD $6.13
- SGMO $0.55
- Analyst Decision
- IHD
- SGMO Strong Buy
- Analyst Count
- IHD 0
- SGMO 7
- Target Price
- IHD N/A
- SGMO $5.29
- AVG Volume (30 Days)
- IHD 27.7K
- SGMO 4.1M
- Earning Date
- IHD 01-01-0001
- SGMO 11-11-2025
- Dividend Yield
- IHD 10.32%
- SGMO N/A
- EPS Growth
- IHD N/A
- SGMO N/A
- EPS
- IHD N/A
- SGMO N/A
- Revenue
- IHD N/A
- SGMO $81,706,000.00
- Revenue This Year
- IHD N/A
- SGMO $21.24
- Revenue Next Year
- IHD N/A
- SGMO N/A
- P/E Ratio
- IHD N/A
- SGMO N/A
- Revenue Growth
- IHD N/A
- SGMO 565.52
- 52 Week Low
- IHD $4.49
- SGMO $0.41
- 52 Week High
- IHD $5.47
- SGMO $3.18
- Technical
- Relative Strength Index (RSI)
- IHD 64.50
- SGMO 54.83
- Support Level
- IHD $6.05
- SGMO $0.49
- Resistance Level
- IHD $6.16
- SGMO $0.56
- Average True Range (ATR)
- IHD 0.06
- SGMO 0.04
- MACD
- IHD 0.01
- SGMO -0.00
- Stochastic Oscillator
- IHD 89.38
- SGMO 81.12
About IHD Voya Emerging Markets High Income Dividend Equity Fund
Voya Emerging Markets High Dividend Equity Fund is a diversified closed-end management investment company. Its primary investment objective is to provide total return through a combination of current income, capital gains, and capital appreciation. The company seeks to achieve its investment objectives by investing principally in a portfolio of equity securities, and issuers in emerging market countries. The Fund will also normally seek to secure gains and enhance the stability of returns over a market cycle by writing (selling) call options on selected exchange-traded funds (ETFs) and/or international, regional, or country indices of equity securities, and/or on equity securities.
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.